Lymphokine activated killer (LAK) activity in lymphoproliferative disorders.
Bone Marrow Transplant
; 4 Suppl 1: 153-5, 1989 Jan.
Article
em En
| MEDLINE
| ID: mdl-2653494
Lymphokine activated killer (LAK) cells are being considered as a new and promising form of immunotherapy in the management of patients with solid tumours. Few informations are instead available on these cytotoxic effectors in haematological neoplasias. Here we shall discuss the possible role of LAK cells in human leukaemias. Evidence will be provided for a rationale in the clinical exploitment of Interleukin 2 (IL2)/LAK cells in the treatment of acute leukaemia patients, whilst the implication of these cytotoxic populations appears more uncertain in chronic lymphoproliferative disorders.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Células Matadoras Naturais
/
Interleucina-2
/
Imunoterapia
/
Transtornos Linfoproliferativos
Tipo de estudo:
Diagnostic_studies
/
Evaluation_studies
Limite:
Humans
Idioma:
En
Revista:
Bone Marrow Transplant
Assunto da revista:
TRANSPLANTE
Ano de publicação:
1989
Tipo de documento:
Article
País de afiliação:
Itália
País de publicação:
Reino Unido